Form Approved
OMB No. 0920-1385
Exp. Date: 3/31/26
Case report form: Chromoblastomycosis in the United States
======================================================
Patient demographic characteristics
Unique patient ID: ___________ (site_####)
Site submitting case: _____________
Location of residence for patient (ZIP Code): _____________ OR [] Unknown
Age at diagnosis (years): ____________
Assigned sex at birth: [] Male [] Female OR [] Unknown
Gender identity: [] Male [] Female [] Transgender, non-binary, or another gender[] Prefer not to answer/Decline OR [] Unknown
Race and/or ethnicity (select all that apply and enter additional details in the spaces provided):
[] American Indian or Alaska Native
Enter, for example, Navajo Nation, Blackfeet Tribe of the Blackfeet Indian Reservation of Montana, Native Village of Barrow Inupiat Traditional Government, Nome Eskimo Community, Aztec, Maya, etc.
[] Asian – provide details below
[] Chinese [] Asian Indian [] Filipino [] Vietnamese [] Korean [] Japanese
Enter, for example, Pakistani, Hmong, Afghan, etc.
[] Black or African American – provide details below
[] African American [] Jamaican [] Haitian [] Nigerian [] Ethiopian [] Somali
Enter, for example, Trinidadian and Tobagonian, Ghanaian, Congolese, etc. ____________________________________________
[] Hispanic or Latino – provide details below
[] Mexican [] Puerto Rican [] Salvadoran [] Cuban [] Dominican [] Guatemalan
Enter, for example, Colombian, Honduran, Spaniard, etc. ____________________________________________
[] Middle Eastern or North African – provide details below
[] Lebanese [] Iranian [] Egyptian [] Syrian [] Iraqi [] Israeli
Enter, for example, Moroccan, Yemeni, Kurdish, etc. ____________________________________________
[] Native Hawaiian or Pacific Islander – provide details below
[] Native Hawaiian [] Samoan [] Chamorro [] Tongan [] Fijian [] Marshallese
Enter, for example, Chuukese, Palauan, Tahitian, etc. ____________________________________________
[] White – provide details below
[] English [] German [] Irish [] Italian [] Polish [] Scottish
Enter, for example, French, Swedish, Norwegian, etc. ____________________________________________
Monthly household income (USD) _____________________________
Occupation at time of presumed infection: ____________________________
Industry at time of presumed infection: ______________________________
======================================================
Underlying medical conditions (active or present in the 2 years before symptom onset)
Diabetes mellitus [] Yes [] No [] Unknown
Chronic kidney disease [] Yes [] No [] Unknown
If yes, on dialysis? [] Yes [] No [] Unknown
If yes, GFR < 60? [] Yes [] No
Liver cirrhosis? [] Yes [] No [] Unknown
Chronic hepatitis without cirrhosis? [] Yes [] No [] Unknown
If yes, [] Hep B [] Hep C
Immunocompromising condition [] Yes [] No [] Unknown
[] HIV infection
[] HIV infection without AIDS (CD4 ≥ 200)
[] HIV infection with AIDS (CD4 < 200) or chart diagnosis of advanced HIV disease
[] Cancer diagnosis, specify ________________
[] On chemotherapy, specify ___________________
Date of cancer diagnosis (mm/dd/yyyy): ________________
[] Transplantation,
[] Solid organ, specify organ ________________
[] Hematologic (stem cell)
Date of transplantation (mm/dd/yyyy): ________________
[] Immunosuppressive therapy, specify ________________
[] Other immunocompromised condition, specify _______________
Other major underlying condition not listed (specify): ________________________
======================================================
Exposure history
Has patient traveled or lived internationally in their life? [] Yes [] No [] Unknown
Country 1 ____________; Approximate duration of stay (years):
Country 2 ____________; Approximate duration of stay (years):
Country 3 ____________; Approximate duration of stay (years):
Country 4 ____________; Approximate duration of stay (years):
Country 5 ____________; Approximate duration of stay (years):
Did the patient immigrate to the United States? [] Yes [] No [] Unknown
If yes, date of immigration (mm/dd/yyyy): _________________ [] Unknown
If yes, country immigrated from: ________________ [] Unknown
Any traumatic inoculation recalled? [] Yes [] No [] Unknown
If yes, please describe geographic location (e.g., city, state): ______________
If yes, please describe the material involved (e.g., thorns, branches): _________
If yes, please describe any weather events (e.g., hurricane, flood): ____________
If yes, please indicate approximate date of traumatic inoculation (mm/dd/yyyy): _____________
Most likely source of infection, according to clinician ________________________________
======================================================
Diagnosis
Did patient have health care facility visits (health center, hospital, etc.) for mycetoma symptoms before visit with mycetoma diagnosis? [] Yes [] No [] Unknown
If yes, how many visits? ____________
Were there misdiagnoses before being diagnosed with mycetoma [] Yes [] No [] Unknown
What misdiagnoses, if any, did this patient have before being diagnosed with mycetoma (in the last 12 months):
Please list all misdiagnoses: ____________________________________________
Laboratory testing (associated with diagnosis):
[] Dermoscopy [] Not performed [] Unknown if performed
date of procedure: ____________
[] Potassium hydroxide preparation [] Not performed [] Unknown if performed
date of preparation: ____________; result: ______________________
[] Skin or surgical biopsy [] Not performed [] Unknown if performed
date of collection (mm/dd/yyyy): ____________; result: ______________________
[] Fungal culture [] Not performed [] Unknown if performed
date of collection (mm/dd/yyyy): ____________; Positive/Negative: _____________ Organism(s): _____________________;
[] Broad range sequencing [] Not performed [] Unknown if performed
date of collection (mm/dd/yyyy): ____________; Type (e.g., 18s, ITS): ____________
Positive/Negative: _____________ Organism(s): _____________________;
======================================================
Signs and symptoms noted in medical chart:
Signs & Symptoms |
Yes/No |
Onset Date |
Warty lesions |
|
|
Raised and crusted lesions |
|
|
Tumors |
|
|
Infiltrative plaques |
|
|
Nodules |
|
|
Polymorphic lesions |
|
|
Migraines |
|
|
Pain |
|
|
Itching |
|
|
Edema |
|
|
Syncope |
|
|
Vomiting |
|
|
Other symptoms, please describe:_______ |
|
|
Please indicate the specific location(s) of the body of the chromoblastomycosis lesions (check all that apply):
[] Head and neck
[] Trunk
[] Upper limbs
[] Buttocks, perineum, genitals
[] Lower limbs
Additional comments on anatomical location: ___________________________________
Disease severity:
[] Mild (solitary plaque or nodule less than 5 cm in diameter)
[] Moderate (single or multiple lesions with nodular, verrucous or plaque morphology, less than 15 cm in diameter, and involving a single or two adjacent skin areas)
[] Severe (extensive involvement of adjacent or nonadjacent skin areas)
Did mycetoma cause any form of disability: [] Yes [] No [] Unknown
If yes, please fill out the table below:
Disability |
Yes/No |
Onset Date |
Number of days with disability |
Inability to walk |
|
|
|
Impacts mobility/ability to walk |
|
|
|
Inability to work |
|
|
|
Treatment
Was the patient treated for chromoblastomycosis?
[] Yes [] No [] Unknown [] Missing/Not documented
If yes, list all therapeutic agents (e.g., antifungals, immune response modulators, antibiotics, steroids) in the table below:
Therapeutic Agent Name |
Max Daily dose (mg/day) |
Route (e.g., IV, PO, IT) |
Start Date |
Duration of Therapy |
Therapy ongoing at time of abstraction |
Discontinued due to toxicity. If yes, describe toxicity |
Therapeutic Drug Monitoring (e.g., serum level of antifungal) |
|
|
|
___ / ___ / ______ |
_____days |
[] Yes [] No |
[] Yes [] No --------------------- --------------------- |
[] Yes [] No
Level 1: Date: Value:
Level 2: Date: Value |
|
|
|
___ / ___ / ______ |
_____days |
[] Yes [] No |
[] Yes [] No --------------------- --------------------- |
[] Yes [] No
Level 1: Date: Value:
Level 2: Date: Value |
|
|
|
___ / ___ / ______ |
_____days |
[] Yes [] No |
[] Yes [] No --------------------- --------------------- |
[] Yes [] No
Level 1: Date: Value:
Level 2: Date: Value |
|
|
|
___ / ___ / ______ |
_____days |
[] Yes [] No |
[] Yes [] No --------------------- --------------------- |
[] Yes [] No
Level 1: Date: Value:
Level 2: Date: Value |
|
|
|
___ / ___ / ______ |
_____days |
[] Yes [] No |
[] Yes [] No --------------------- --------------------- |
[] Yes [] No
Level 1: Date: Value:
Level 2: Date: Value |
|
|
|
___ / ___ / ______ |
_____days |
[] Yes [] No |
[] Yes [] No --------------------- --------------------- |
[] Yes [] No
Level 1: Date: Value:
Level 2: Date: Value |
Notes about treatment: __________________________________________________________________________________________________________________________________________________________________________
Did the patient undergo surgical excision of the chromoblastomycosis lesion(s): [] Yes [] No [] Unknown
If yes, date of surgical excision (mm/dd/yyyy): _____________
Did the patient have cryotherapy: [] Yes [] No [] Unknown
Did the patient have heat therapy: [] Yes [] No [] Unknown
Did the patient have light-based therapy: [] Yes [] No [] Unknown
======================================================
Complications:
Outcome |
Yes/No |
Onset Date |
Notes (e.g., location) |
Tissue fibrosis |
|
|
|
Secondary bacterial infection |
|
|
|
Squamous cell carcinoma |
|
|
|
Internal organ involvement |
|
|
|
Amputation |
|
|
|
Lymphedema |
|
|
|
Did the chromoblastomycosis infection resolve? [] Yes [] No [] Since
If yes, what was the date of clinical resolution (disappearance of cutaneous manifestations with the exception of atrophic scarring) (mm/dd/yyyy):
If no, what was date of last follow-up (mm/dd/yyyy):
Did this patient die within 2 years after the chromoblastomycosis diagnosis? [] Yes [] No [] Unknown
If yes, was chromoblastomycosis a contributing factor in patient’s death? [] Yes [] No [] Unknown
Additional comments: __________________________________________________________________________________________________________________________________________________________________________
Appendix 2: Dermatology Life Quality Index Tool
Dermatology Life Quality Index Questionnaire:
Over the last week, how itchy, sore, painful, or stinging has your skin problem been?
Very much
A lot
A little
Not at all
Over the last week, how embarrassed or self-conscious have you been because of your skin problem?
Very much
A lot
A little
Not at all
Over the last week, how much has your skin problem interfered with you going shopping or looking after your home or garden?
Very much
A lot
A little
Not at all
Not relevant
Over the last week, how much has your skin problem influenced the clothes you wear?
Very much
A lot
A little
Not at all
Not relevant
Over the last week, how much has your skin problem affected any social or leisure activities?
Very much
A lot
A little
Not at all
Not relevant
Over the last week, how much has your skin problem made it difficult for your to do any sport?
Very much
A lot
A little
Not at all
Not relevant
Over the last week, has your skin problem prevented you from working of studying
Yes
No
Not relevant
If no, over the last week how much has your skin problem been a problem at work or studying?
A lot
A little
Not at all
Over the last week, how much has your skin problem created problems with your partner or any of your close friends or relatives?
Very much
A lot
A little
Not at all
Not relevant
Over the last week, how much has your skin problem caused any sexual difficulties?
Very much
A lot
A little
Not at all
Not relevant
Over the last week, how much of a problem has the treatment for your skin problem been, for example by making your home messy, or by taking up time?
Very much
A lot
A little
Not at all
Not relevant
CDC estimates the average public reporting burden for this collection of information as 30 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS H21-8, Atlanta, Georgia 30333; ATTN: PRA (0920-1385).
File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
Author | Smith, Dallas (CDC/DDID/NCEZID/DFWED) |
File Modified | 0000-00-00 |
File Created | 2025-01-17 |